Hyper-CVAD + Rituximab (CD20+) — alternating courses A/B, 8 cycles total
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | None declared |
|---|
| ID | REG-HYPER-CVAD-R |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead approval. MD Anderson regimen (Kantarjian et al). Add dasatinib/ponatinib continuously for Ph+. POMP maintenance (POMP = Prednisone+Oncovin+MTX+Purinethol) × 30 months after induction.
Used By
Indication
IND-B-ALL-1L-PH-NEG- IND-B-ALL-1L-PH-NEGIND-B-ALL-1L-PH-POS- IND-B-ALL-1L-PH-POSIND-BURKITT-1L-HYPERCVAD-R- IND-BURKITT-1L-HYPERCVAD-RIND-T-ALL-1L-HYPER-CVAD- IND-T-ALL-1L-HYPER-CVAD